Show
Sort by
-
Towards a diagnostic and therapeutic consensus in male osteoporosis
-
Sustained 5-year vertebral and non-vertebral fracture risk reduction with strontium ranelate in elderly women with osteoporosis
-
Strontium ranelate reduces the risk of fracture in elderly women with osteoporosis in the first year of treatment
-
Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older
-
The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis
-
Strontium ranelate reduces the vertebral fracture risk in women with postmenopausal osteoporosis
-
Strontium ranelate reduces the vertebral fracture risk in women with postmenopausal osteoporosis.
-
Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids - A randomized, double-blind, placebo-controlled extension trial.
-
Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis.